Cancer and dendritic cells recognise and migrate towards chemokines secreted from lymphatics, and use this mechanism to invade the lymphatic system, and cancer cells, metastasise through it. The lymphatic secreted chemokine ligand CCL21 has been identified as a key regulatory molecule in the switch to a metastatic phenotype in melanoma and breast cancer cells. However, it is not known whether CCL21 inhibition is a potential therapeutic strategy for inhibition of metastasis. Here, we describe an engineered CCL21 soluble inhibitor, Chemotrap-1, which inhibits migration of metastatic melanoma cells in vivo. Two-hybrid, pull down and co-immunoprecipitation assays allowed us to identify a naturally occurring human zinc finger protein with CCL21 chemokine-binding properties. Further analyses revealed a short peptide (~ 70 aminoacids), with a predicted coiled-coil structure, which is sufficient for association with Together, these results show that CCL21 chemokine inhibition by Chemotrap-1 is a potential therapeutic strategy for metastasis, and provide further support for the hypothesis that lymphatic mediated metastasis is a chemokine-dependent process.
Introduction
Tumour metastasis occurs either through the lymphatic or the vascular systems.
Lymphatic metastasis is the most common route for melanoma, breast, prostate, and other cancers. When they metastasise specifically through the lymphatic system, tumour cells locate and recognise lymphatic endothelial cells (LEC). The secreted lymphatic chemokine CCL21 is released from LEC(1), and is used by dendritic cells (DC) to guide their invasion into lymphatics by acting on its receptor CCR7, expressed on DCs(2). CCR7 expression is increased in patients with metastatic melanoma(3), prostate(4), head and neck (5) and squamous cell carcinoma (6) and breast cancer(7) compared with nonmetastatic cancers. Thyroid, lung, oral squamous cell carcinoma, melanoma and breast cancer cells that upregulate receptors for lymphatic secreted chemokines such as CCL21 are more likely to metastasise (3, (8) (9) (10) . It has therefore been hypothesised that CCR7 is used by metastatic melanoma cells to detect locally secreted lymphatic specific chemokines such as CCL21, and migrate towards it to find areas of increased lymphatic density (11) . One potential therapeutic strategy to prevent metastasis would be to inhibit this chemokine mediated entry of cancer cells into lymphatics. Therapeutic strategies based on soluble human receptors prepared as Fc-fusion proteins, termed Traps, have been successfully developed for several cytokines, including TNFα (Etanercept) (12, 13) , IL-1 (IL-1-Trap) (14) and VEGF (Aflibercept) (15) . These are generated using the fixed GST pull-down and co-immunoprecipitation assays. GST and GST-THAP1 fusion proteins were produced and purified as previously described (17) . In vitro-translated hCCL21, mCCL21, hCCL27 and hCCL21ΔCOOH, were generated with the TNTcoupled reticulocyte-lysate system (Promega, Madison, WI, USA) using pGADT7-hCCL21, -mCCL21, -hCCL27 or -hCCL21ΔCOOH as template. 25μl of 35 S-labelled chemokines were incubated with immobilized GST-THAP1 or GST proteins overnight at 4°C, in 10mM NaPO 4 pH8.0, 140mM NaCl, 3mM MgCl 2 , 1mM dithiothreitol (DTT), 0.05%NP40, 0.2mM phenylmethyl sulphonyl fluoride (PMSF), 1mM Na Vanadate, 50mM β glycerophosphate, 25μg/ml chymotrypsin, 5μg/ml aprotinin, 10 μg/ml leupeptin. Beads were washed 5 times in 1ml binding buffer. Bound proteins were eluted with 2X Laemmli SDS-PAGE sample buffer, fractionated by 10% SDS-PAGE and visualized by fluorography using Amplify (Amersham Pharmacia Biotech). For coimmunoprecipitation experiments, U2OS cells were transfected with plasmids encoding CCL21-Flag and/or HA-THAP1 using a calcium-phosphate precipitation procedure. Two days after transfection, cellular extracts were prepared 15mM Tris-HCl, pH 7.5, 0.4M NaCl, 5mM MgCl 2 , 0.1%Tween 20 containing protease and phosphatase inhibitors (Roche). After three freeze/thawing cycles, cellular extracts were centrifuged at 12000g for 10 min, then precleared at 4°C for 1h in a rotating wheel with 20µl protein Gsepharose beads (Amersham). Beads were precipitated by centrifugation, and supernatants incubated overnight at 4°C with 5µg of Flag M2 antibody (Sigma). Immune In silico sequence analysis and molecular modeling -Coiled-coil predictions were performed at PAIRCOIL (http://paircoil.lcs.mit.edu/cgi-bin/paircoil) and MULTICOIL (http://multicoil.lcs.mit.edu/cgi-bin/multicoil) web sites. The structure of the THAP1 dimeric coiled-coil was built by homology with the X-ray structure of the GCN4 parallel coiled-coil (PDB code:1KD8). The energy of the interaction interface was minimized by using the Affinity module within InsightII (Accelrys, San Diego, CA).
Generation of Chemotrap-1 expression vector -The sequence encoding residues 140
to 213 of human THAP1 was amplified by PCR with oligonucleotides THAP1-XhoI-5'(5'-ccgctcgaggatacaatgcacc-3') and THAP1-BamH1-3'(5'-gcgggatccgctggtacttcaacta tttcaaag-3'). The resulting XhoI-BamHI fragment was used to replace the XhoI-BamHI fragment encoding L-selectin in the pCDM8-L-selectin-IgG1 plasmid (18, 19 
Surface plasmon resonance (SPR) experiments

ELISA.
The CCL21 DuoSet ELISA was carried out as per manufacturers instructions. To determine the effect of chemotrap-1 on CCL21 release from LEC, cells were cultured for 24 hours in 0.5%EGM2, and 5ml media transferred to a T25 flask of B16 melanoma cells for a further 24 hours. Media was then collected, spun to remove cells, and then concentrated through an Amicon10000 spin column.
In vitro Cell migration
Migration assays were performed in a modified Boyden chamber consisting of a cell culture insert with an 8µm pore polycarbonate membrane (Millipore) seated in each well of a 24 well plate as previously described (11) . For dose-response migration assays were performed as above in 150ng/ml CCL21 and increasing concentrations of chemotrap. The number of cells migrated through were normalised to the lowest concentration of chemotrap (10pM) and to 0.1% FCS alone (no CCL21), and EC50 determined by nonlinear curve fitting with fixed top and bottom parameters (100% and 0% respectively) using a sigmoidal dose response curve.
In vivo Metastatic chemotaxis model
Experiments were carried out as previously described (11) . Briefly, nude mice were injected with 1x10 
Results
Identification of a CCL21-chemokine-binding protein.
While searching for CCL21-interacting proteins in a two-hybrid screen of a high endothelial venule (HEV) cDNA library, we identified the cDNA encoding a novel nuclear factor, that we designated THAP1 (17) . Eight positive clones (of five million transformants) were identified with the CCL21 bait, and all corresponded to the Cterminal part of THAP1, aa 90-213 ( proteins bind to GST-THAP1 but not to GST (Fig. 1A) . the interaction was also observed when the basic C-terminal extension of CCL21 was deleted, indicating that THAP1
interacts with the core chemokine domain of CCL21 (Fig. 1A) . No binding of THAP1 was observed to CCL27, another CC chemokine. We next addressed whether THAP1 is able to interact with CCL21 in cells. We performed immunoprecipitation experiments in cells co-expressing epitope-tagged-CCL21 (Flag-CCL21) and -THAP1 (THAP1-HA).
We observed specific immunoprecipitation of THAP1 with anti-Flag antibodies in cells co-expressing Flag-CCL21, whereas no precipitation of THAP1 with anti-Flag antibodies was observed in control cells (Fig. 1B) . These findings demonstrated that THAP1
interacts with CCL21 both in vitro and in cells. To determine the kinetic parameters of the THAP1/CCL21 complex, we performed SPR. THAP1 1-213 -Fc fusion protein was purified from cell supernatants and immobilized on a sensor chip. Addition of purified recombinant human CCL21 revealed association with immobilized THAP1 1-213 -Fc with a Kd of 87 nM (Fig. 1C) . Together, our observations indicated that the human THAP-zinc finger protein THAP1 is a chemokine-binding protein that binds CCL21 with nanomolar affinity.
Mapping the CCL21 chemokine-binding domain.
To identify sequences mediating CCL21-binding, a series of THAP1 deletion mutants were generated. These truncated versions were used as Gal4 DNA-binding domain fusion proteins (baits) in the Y2H system, together with preys corresponding to mature CCL21
(aa 24-134) in fusion with the Gal4 activating domain. Schematic representation of all THAP1 deletion mutants and summary of two-hybrid results are presented in Fig. 2A . 
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Copyright © 2010 American Association for Cancer Research domain with seven heptad repeats (49 residues), extending between amino acids 142 and 190 of human THAP1. The probability for formation of the coiled-coil structure of this region was 1 (maximum score) with both programs, indicating that this region of THAP1 has a very high probability of existing as a coiled-coil structure (Fig. 2C ). Molecular modeling of the THAP1 coiled-coil domain was performed using the X-ray crystal structures of known coiled-coil domains as a template. The resulting three-dimensional model of the THAP1 coiled-coil is shown in Figure 2D The CCL21 chemokine-binding domain of THAP1 could be useful to engineer a high affinity soluble inhibitor capable of blocking CCL21 chemokine activity in vivo. We thus generated a fusion protein between the Fc region of human IgG1 and the CCL21 chemokine-binding domain of human THAP1 (Fig. 3A) . This fusion proteinChemotrap-1 -was then expressed in chinese hamster ovary (CHO) cells and purified.
As a negative control, we generated a fusion protein of human IgG1 with a 26 amino acid region (aa 189-213) of THAP1 that does not bind CCL21 (Fig 2B) . Chemotrap-1 bound to CCL21 with the same affinity as the full length THAP1-IgG1 fusion protein (~ 100 nM), 
Copyright © 2010 American Association for Cancer Research as determined by SPR (Fig. 3B) . In contrast, Chemotrap-189 did not bind CCL21 (data not shown).
To determine whether Chemotrap-1 could inhibit CCL21 chemokine-mediated migration of cancer cells, we seeded A375P-CCR7 transfected melanoma cells on polycarbonate inserts, and measured migration across those inserts to CCL21, or CCL21
and Chemotrap-1. 1µg/ml Chemotrap-1 significantly inhibited migration of these melanoma cells towards 150ng/ml CCL21 (Fig 3C) . To determine the potency of Chemotrap-1 in vitro we performed a dose escalating study using 150ng/ml CCL21 as a pro-migration agent. Figure 3D shows that chemotrap-1 dose dependently inhibited CCL21 mediated migration with an IC50 of 77pM, significantly more potent than to immobilised CCL21 on a chip in vitro. To determine the specificity of chemotrap-1 in vitro we investigated its effect on migration of A375P-CCR7 cells induced by three different chemokines -CCL19 (binds CCR7), CXCL12 (binds CXCR4) and CXCL10
(binds CXCR3). 150ng/ml of any of the four chemokines induced migration of melanoma cells, but only the CCR7 ligands, CCL21 and CCL19 were inhibited by Chemotrap-1 ( figure 3E ).
Chemotrap-1 blocks migration of metastatic melanoma cells towards lymphatics in vitro and in vivo.
We previously showd metastatic melanoma cells migrating towards LEC conditioned medium in a CCL21 dependent manner (11) . To determine whether this could be inhibited (Fig. 4B ). Tumours were excised, pronated and the area of tumour on each side of the injection site was quantified. Figure 4C shows Chemotrap-1 expression resulted in a statistically significant inhibition of tumour growth towards LEC, to a level equivalent to non-directed growth (towards the site of a saline injection).
Chemotrap-1 prevents in transit metastasis of melanoma cells in lymphatics in vivo.
CCR7 over-expression increases lymph node metastasis of B16 mouse metastatic melanoma cells, resulting from uptake into and tracking along the local lymphatics (24) .
To determine whether Chemotrap-1 could inhibit this tracking, in a CCR7-dependent To confirm that Chemotrap-1 was being secreted from the transfected cells used a commercial DuoSet CCL21 ELISA. Figure 5F shows that the melanoma cells do not express CCL21 at levels detectable on the CCL21 Duoset Kit, (confirmed by RT-PCR, data not shown). LEC expressed CCL21 protein (1.79pg/ml per flask per hour) and mRNA as determined by RT-PCR (data not shown). When LEC CM was mixed with media from Chemotrap-1 expressing cells (B16-CT1), there was a reduction in available CCL21 indicating binding of CCL21 to Chemotrap-1 to below the detection limit of the assay. In contrast when LEC-CM was added to Chemotrap-189 there was no reduction in CCL21.
Discussion.
Metastatic mechanisms are potential therapeutic targets, as cancers can be detected and excised before metastasis is apparent, yet spread months or even years after excision. For melanoma, prognosis is poor once metastasis has occurred and there are no widely accepted therapies. We show here that one mechanism of metastasis, chemokine mediated LEC targeting, is potentially therapeutically amenable, as inhibition of the CCL21/CCR7 axis can prevent melanoma cells recognising and migrating towards areas of high lymphatic density, and invading those lymphatics.
Chemokine receptors, including the CCL21 receptor CCR7, and the CXCL12 receptor CXCR4 have been associated with metastatic melanoma in humans, and increase metastatic growth in mouse and human tumours in experimental animals (3, 25) . Two non-mutually exclusive mechanisms have been proposed for CCR7-CCL21 mediated metastasis, metastatic chemotaxis towards areas of high lymphatic density(11), and autologous chemotaxis (26) . Current experiments did not determine the relative Another chemokine-binding protein, the M3 protein encoded by murine gammaherpesvirus-68, has previously been shown to bind CCL21 with high affinity and to inhibit CCL21-mediated recruitment of lymphocytes in vivo (28) . A major advantage of Chemotrap-1 is that it is a fully human recombinant protein. The M3 protein also binds and blocks the activity of other chemokines in vivo (28) and it will be important in future studies to widen the chemokines against which Chemotrap-1 has been tested to understand the full binding potential of this protein.
Most human melanomas metastasise through the local lymphatics and, through the lymph node, gain access to the circulation and reach distant organs such as the lung, brain, liver, etc. We therefore used a model in experimental animals whereby lymphatic metastasis is generated from subcutaneous injection of primary tumour cells, in contrast with experimental models using intravenous injection of tumour cells. This is not the usual route for melanoma metastasis. In patients, melanomas can form secondary lesions either locally within the skin (local metastasis), along the lymphatics (in transit metastasis), or distantly (lymph node, primarily, followed by brain, lung, liver, etc). We show here that chemokine-binding agents can prevent melanoma migration towards areas of high lymphatic density, invasion into lymphatics, and in transit metastasis.
The findings here indicate that inhibition of chemokines acting on tumour cells can prevent tumour migration towards and into draining lymphatics. This suggests that chemokine antagonists may be potential therapeutic agents. Further evidence for this would be required before moving to clinical studies, particularly in terms of generating each residue within the THAP1 sequence contributing to a coiled-coil structure, is plotted (maximal probability score=1). D-Molecular modeling of the THAP1 coiled-coil domain based on the crystallographic structure of the GCN4 homodimeric parallel coiled-coil.
Molecular modelling was performed as described in the Materials and Methods. melanoma cells in the foot pad. 22 days later the tumours were imaged by bioluminescence (i) and then the mouse killed and the lymph node exposed and imaged
(ii). E. Chemotrap-1 treatment significantly reduced the incidence of lymph node
